Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
Active, not recruiting · NCT05715281 · Registry updated 2025-11-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | Advanced Rare Malignant Solid Neoplasm; Rare Malignant Solid Neoplasm; Refractory Rare Malignant Solid Neoplasm | Active, not recruiting | Phase 2 | 2025-11-25 | NCT05715281 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda | United States | 28 |
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |